Chinese General Practice ›› 2020, Vol. 23 ›› Issue (7): 880-883.DOI: 10.12114/j.issn.1007-9572.2019.00.619
Special Issue: 共病最新文章合集
• Monographic Research • Previous Articles Next Articles
Published:
2020-03-05
Online:
2020-03-05
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2019.00.619
[1]BARY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer Journal for Clinicians,2018,68(6):1-31.DOI:10.3322/caac.21492. [2]兰蓝,赵飞,蔡玥,等.中国居民2015年恶性肿瘤死亡率流行病学特征分析[J].中华流行病学杂志,2018,39(1):32-34.DOI:10.3760/cma.j.issn.0254-6450.2018.01.006. LAN L,ZHAO F,CAI Y,et al.Epidemiological analysis on mortality of cancer in China,2015[J].Chinese Journal of Epidemiology,2018,39(1):32-34.DOI:10.3760/cma.j.issn.0254-6450.2018.01.006. [3]HOFFE S,BALDUCCI L.Cancer and age:general considerations[J].Clin Geriatr Med,2012,28(1):1-18.DOI:10.1016/j.cger.2011.09.001. [4]BRIGHI N,BALDUCCI L,BIASCO G.Cancer in the elderly:is it time for palliative care in geriatric oncology?[J].Journal of Geriatric Oncology,2014,5(2):197-203.DOI:10.1016/j.jgo.2014.01.007. [5]刘文斌.社区老年人高血压流行病学调查[J].中国全科医学,2011,14(3):300-302.DOI:10.3969/j.issn.1007-9572.2011.03.025. LIU W B.Epidemiological survey of hypertension in aged patients of the community[J].Chinese General Practice,2011,14(3):300-302.DOI:10.3969/j.issn.1007-9572.2011.03.025. [6]NQ H S,KOCZWARA B,RODER D,et al.Changes in the prevalence of comorbidity in the Australian population with cancer,2007—2014[J].Cancer Epidemiology,2018,54:56-62.DOI:10.1016/j.canep.2018.03.010. [7]MORISHIMA T,MIYASHIRO I,MATSUMOTO Y,et al.Impact of comorbidities on survival in gastric,colorectal,and lung cancer patients[J].Journal of Epidemiology,2018,14:1-6.DOI:10.2188/jea.JE20170241. [8]FEINSTEIN A R.The pre-therapeutic classification of co-morbidity in chronic disease[J].J Chron Dis,1970,23:455-468.DOI:10.1016/0021-9681(70)90054-8. [9]World Health Organization.The world health report 2008:primary health cared now more than ever[R].Geneva:World Health Organization,2008. [10]于普林.老年医学[M].北京:人民卫生出版社,2017. [11]MENESES K,BENZ R,AZUERO A,et al.Multimorbidity and breast cancer[J].Seminars in Oncology Nursing,2015,31(2):163-169.DOI:10.1016/j.soncn.2015.02.004. [12]崔瑶,刘谦,秦明照.老年共病现状及管理策略[J].中国全科医学,2017,20(23):2816-2819.DOI:10.3969/j.issn.1007-9572.2017.06.y54. CUI Y,LIU Q,QIN M Z.Status and management strategies of multiple chronic conditions in older adults[J].Chinese General Practice,2017,20(23):2816-2819.DOI:10.3969/j.issn.1007-9572.2017.06.y54. [13]周玉洁,吕启圆,李现文.共病及共病指数研究进展与应用展望[J].中国公共卫生,2015,34(11):1513-1516.DOI:10.11847/zgggws2015-31-11-44. ZHOU Y J,Lyu Q Y,LI X W.Comorbidity and comorbidity index:a review[J].Chin J Public Health,2015,34(11):1513-1516.DOI:10.11847/zgggws2015-31-11-44. [14]蒲莉蓉,王敏,李志雄,等.边缘型人格障碍与精神疾病共病的研究进展[J].中国神经精神疾病杂志,2019,45(4):250-253. PU L R,WANG M,LI Z X,et al.Research progress on comorbidity between borderline personality disorder and mental illness[J].Chinese Journal of Neuropsychiatric Diseases,2019,45(4):250-253. [15]KENZIK K M,KENT E E,MARTIN M Y.Chronic condition clusters and functional impairment in older cancer survivors:a population-based study[J].J Cancer Surviv,2016,10(6):1096-1103.DOI:10.1007/s11764-016-0553-4. [16]胡小兰.社区老年慢性非传染性疾病共病的现况调查[D].北京:首都医科大学,2015. [17]王飞虎,张璐.抗抑郁药治疗偏头痛与抑郁症共病的研究进展[J].中国乡村医药,2019,26(7):74-75.DOI:CNKI:SUN:XCYY.0.2019-07-048. WANG F H,ZHANG L.Research progress in the treatment of migraine and depression with antidepressant[J].Chinese rural medicine,2019,26(7):74-75.DOI:CNKI:SUN:XCYY.0.2019-07-048. [18]GUISADOCLAVERO M,ROSOLLORACH A,LóPEZJIMENEZ T,et al.Multimorbidity patterns in the elderly:a prospective cohort study with cluster analysis[J].BMC Geriatrics,2018,18(1):16.DOI:10.1186/s12877-018-0705-7. [19]WILLIAMS G R,DEAL A M,LUND J L,et al.Patient-reported comorbidity and survival in older adults with cancer[J].Oncologist,2017,23(4):1-7.DOI:10.1634/theoncologist.2017-0404. [20]METTE S,WERNICH T R,SKOVGAARD B K,et al.The impact of comorbidity on cancer survival:a review[J].Clinical Epidemiology,2013,5(1):3-29.DOI:10.2147/CLEP.S47150. [21]J?RGENSEN T L,HALLAS J,FRIIS S,et al.Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality[J].British Journal of Cancer,2012,106(7):1353-1360.DOI:10.1038/bjc.2012.46. [22]ALEXANDRA P T,AMAIA C L,JORGE H S,et al.Multimorbidity patterns:a systematic review[J].Journal of Clinical Epidemiology,2014,67:254-266.DOI:10.1016/j.jclinepi.2013.09.021. [23]OKEDIJI P T.The pattern of comorbidities in cancer patients in Lagos,South-Western Nigeria[J].Ecancer Medical Science,2018,12(843):1-12.DOI:10.3332/ecancer.2018.843. [24]WU A H,KURIAN A W,KWAN M L,et al.Diabetes and other comorbidities in breast cancer survival by race/ethnicity:the California Breast Cancer Survivorship Consortium(CBCSC)[J].Cancer Epidemiol Biomarkers Prev,2015,24(2):361-368.DOI:10.1158/1055-9965.EPI-14-1140. [25]XUE S,ZE C,WILSON K.Real-world treatment patterns,comorbidities,and disease-related complications in patients with multiple myeloma in the United States[J].Current Medical Research & Opinion,2016,32(1):95-103.DOI:10.1185/03007995.2015.1105202. [26]SARFATI D.Review of methods used to measure comorbidity in cancer populations:no gold standard exists[J].Journal of Clinical Epidemiology,2012,65(9):924-933.DOI:10.1016/j.jclinepi.2012.02.017. [27]GANTI A K,SIEDLIK E,MARR A S,et al.Predictive ability of charlson comorbidity index on outcomes from lung cancer[J].American Journal of Clinical Oncology,2011,34(6):593-596.DOI:10.1097/COC.0b013e3181fe445b. [28]CHARLSON M E,POMPEI P,ALES K L.A New method of classifving prognostic comorbidity in longitudinal studies:development and validation[J].J Chronic Dis,1987,40(5):373-383.DOI:10.1016/0021-9681(87)90171-8. [29]WU C,HSU T,CHANG C,et al.Age-adjusted Charlson comorbidity index scores as predictor of survival in colorectal cancer patients who underwent surgical resection and chemoradiation[J].Medicine,2015,94(2):e431.DOI:10.1097/MD.0000000000000431. [30]SINGH B,BHAYA M,STERN J,et al.Validation of the Charlson comorbidity index in patients with head and neck cancer:a multi-institutional study[J].The Laryngoscope,1997,107(11 Pt 1):1469-1475.DOI:10.1097/00005537-199711000-00009. [31]LEE J Y,LEE D H,CHO N H,et al.Impact of Charlson comorbidity index varies by age in patients with prostate cancer treated by radical prostatectomy:a competing risk regression analysis[J].Annals of Surgical Oncology,2014,21(2):677-683.DOI:10.1245/s10434-013-3326-6. [32]王灯英.某三甲医院住院患者营养状况与老年共病相关性及其干预研究[D].青岛:青岛大学,2017. [33]SARIFATI D,KOCZWARA B,JACKSON C.The impact of comorbidity on cancer and its treatment[J].A Cancer Journal for Clinicians,2016,66:337-350.DOI:10.3322/caac.21342. [34]AHN D H,MEHTA N,YORIO J T,et al.Influence of medical comorbidities on the presentation and outcomes of stage i-iii non-small-cell lung cancer[J].Clinical Lung Cancer,2013,14(6):644-650.DOI:10.1016/j.cllc.2013.06.009. [35]GRANN A F,FROSLEV T,OLESEN A B,et al.The impact of comorbidity and stage on prognosis of Danish melanoma patients,1987—2009:a registry-based cohort study[J].British Journal of Cancer,2013,109(1):265-271.DOI:10.1038/bjc.2013.246. [36]李苏宜,沈干.肿瘤患者的“共病”[J].中国临床保健杂志,2016,19(5):449-450.DOI:10.3969/J.issn.1672-6790.2016.05.001. LI S Y,SHEN G.Comorbidity of cancer patients[J].Chinese Journal of Clinical Health Care,2016,19(5):449-450.DOI:10.3969/J.issn.1672-6790.2016.05.001. [37]PETRILLO L A,RITCHIE C S.The challenges of symptom management for patients with multimorbidity in research and practice:a thematic review[J].Progress in Palliative Care,2016,24(5):262-267.DOI:10.1080/09699260.2016.1192320. [38]LEE L,CHEUNG W Y,ATKINSON E,et al.Impact of comorbidity on chemotherapy use and outcomes in solid tumors:a systematic review[J].J Clin Oncol,2011,29:106-117.DOI:10.1586/17474086.2015.1024650. [39]SARFATI D,GURNEY J,STANLEY J,et al.A retrospective cohort study of patients with stomach and liver cancers:the impact of comorbidity and ethnicity on cancer care and outcomes[J].BMC Cancer,2014,14:821.DOI:10.1186/1471-2407-14-821. [40]JORGENSEN T L,TEIBLUM S,PALUDAN M,et al.Significance of age and comorbidity on treatment modality,treatment adherence,and prognosis in elderly ovarian cancer patients[J].Gynecologic Oncology,2012,127(2):367-374.DOI:10.1016/j.ygyno.2012.07.001. [41]BRADLEY C J,DAHMAN B,ANSCHER M.Prostate cancer treatment and survival evidence for men with prevalent comorbid conditions[J].Medical care,2014,52:482-489.DOI:10.1097/MLR.0000000000000113. [42]KORENHAKIM T,WEISS A,HERSHKOVITZ A,et al.The relationship between nutritional status of hip fracture operated elderly patients and their functioning,comorbidity and outcome[J].Clinical Nutrition,2012,6(1):917-921.DOI:10.1016/j.clnu.2012.03.010. [43]SOGAARD M,THOMSEN R,BOSSEN K,et al.The impact of comorbidity on cancer survival:a review[J].Clin Epidemiol,2013,5:3-29.DOI:10.2147/CLEP.S47150. [44]TüZüN H,AYCAN S,LHAN M N.Impact of comorbidity and socioeconomic status on quality of life in patients with chronic diseases who attend primary health care centres[J].Central European Journal of Public Health,2015,23(3):188-194.DOI:10.21101/cejph.a3990. [45]BACKEMAR L,WIKMAN A,DJ?RV T,et al.Co-morbidity after oesophageal cancer surgery and recovery of health-related quality of life[J].British Journal of Surgery,2016,103(12):1665-1675.DOI:10.1002/bjs.10248. [46]DOUNYA S,KAMILA C,PER H.The Impact of co-morbidity on health-related quality of life in breast cancer survivors and controls[J].Acta Oncologica,2015,54(5):727-734.DOI:10.3109/0284186X.2014.998277. [47]VISSERS P A,THONG M S,POUWER F,et al.The impact of comorbidity on health-related quality of life among cancer survivors:analyses of data from the profiles registry[J].J Cancer Surviv,2013,7:602-613.DOI 10.1007/s11764-013-0299-1. [48]WILLIAMS G R,MACKENZIE A,MAGNUSON A,et al.Comorbidity in older adults with cancer[J].Journal of Geriatric Oncology,2015,7(4):249-257.DOI:10.1016/j.jgo.2015.12.002. LIU S.The phenomenon of "abuse of the elderly" in China,its causes and countermeasures[J].Chinese Journal of Gerontology,2016,36(1):221-223. |
[1] | LI Qianqian, CHEN Xunrui, ZHANG Wenying, YUAN Haihua, ZHANG Yanjie, JIANG Bin, LIU Feng. Demand and Influencing Factors for Community Health Services during Chemotherapy of Patients with Advanced Cancer [J]. Chinese General Practice, 2023, 26(33): 4173-4180. |
[2] | LI Jilei, LI Honglin, XU Yanchao, LIU Yanan, CHEN Mengli, SHAO Shuai, MA Chunzheng. Clinical Study on the Combination of Xiaotan Huayu Tongyi Granules, Channel Kaijie Pills and Chemotherapy in the Treatment of Esophageal Cancer [J]. Chinese General Practice, 2023, 26(30): 3759-3764. |
[3] | ZHENG Yuling, ZHANG Yaling, LIU Huaimin, XU Yanchao, JIA Xiaolin, LI Junsai, HE Wenlong, TONG Xinduo, QIN Shanwen, ZHANG Lihan. Clinical Observation of Dingxiang Guanshitong Hanhua Pills Alone and Its Combination with Fugui Guanshitong Granules in the Treatment of Advanced Esophageal Cancer [J]. Chinese General Practice, 2023, 26(30): 3765-3771. |
[4] | YAN Ke, WEI Wanyi, LI Shuguang, YAO Weinan, DONG Jing, WANG Xiaobin, ZHANG Xueyuan, YANG Jie, SHEN Wenbin, ZHU Shuchai. Effect of Consolidation Chemotherapy on Prognosis of StageⅡ-Ⅲ Esophageal Squamous Cell Carcinoma Patients Treated with Definitive Concurrent Chemotherapy and Radio-therapy [J]. Chinese General Practice, 2023, 26(30): 3772-3779. |
[5] | YAN Ke, WEI Wanyi, DENG Wenzhao, SHEN Wenbin, LI Shuguang, DU Xingyu, ZHANG Xueyuan, YANG Jie, ZHU Shuchai. Long-term Prognosis Analysis and Influencing Factors of Concurrent Chemotherapy and Radio-therapy for Cervical and Upper Thoracic Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2023, 26(30): 3785-3790. |
[6] | PAN Ye, LIU Zhihui, HU Qianqian, WANG Liuyi. Patterns of Coexistence of Multiple Chronic Conditions among Chinese Elderly [J]. Chinese General Practice, 2023, 26(29): 3608-3615. |
[7] | WANG Xiaoran, ZHANG Dan. Influence of Multimorbidity on Anxiety Symptoms among Chinese Elderly People: a Propensity Score-matched Study [J]. Chinese General Practice, 2023, 26(29): 3622-3627. |
[8] | HE Li, ZHANG Yifan, SHEN Xuechun, SUN Yan, ZHAO Yang. Prevalence Trends of Multimorbidity among Residents in Mainland China: a Meta-analysis [J]. Chinese General Practice, 2023, 26(29): 3599-3607. |
[9] | HU Jingyi, HONG Jing, GUO Xiaodong, ZHANG Xiaohong, MO Ning, ZHOU Xiaocui, YU Qin, ZHOU Minhua, SUN Yan, NI Liu, SHI Xiaoli, SU Xiaoqing, LI Yuqian. Efficacy of Community-involved Hospice Care for Patients with Advanced Cancer: a Meta-analysis [J]. Chinese General Practice, 2023, 26(28): 3573-3584. |
[10] | DUAN Yuxia, LI Zhen, ZHANG Siqi, FANG Zhixue, QIN Yuelan. Effect of Patient Decision Aids in the Diagnosis and Treatment of Colorectal Cancer: a Systematic Review [J]. Chinese General Practice, 2023, 26(25): 3194-3201. |
[11] | WANG Rui, WANG Xiaomei, PENG Guoqing, YU Huan, WANG Sihan, XIA Jin. Screening Assessment and Therapy Intervention of Cancer Cachexia in Adult Patients——Based on the Interpretation of Cancer Cachexia in Adult Patients: ESMO Clinical Practice Guidelines [J]. Chinese General Practice, 2023, 26(23): 2823-2829. |
[12] | ZHENG Xiao, TIAN Feng, CHEN Yiming, XUE Benli, SHI Lei, ZHANG Chichen. Research Hotspots and Evolutionary Trends on Multimorbidity in China from 2002 to 2022 [J]. Chinese General Practice, 2023, 26(21): 2567-2573. |
[13] | FENG Jia, WANG Jie, YU Dan, LIU Yongheng, ZHAO Weidong, TIAN Hongyuan. Analysis of Research Hotspots of Multiple Chronic Conditions in the Elderly in 2010-2021 [J]. Chinese General Practice, 2023, 26(21): 2574-2580. |
[14] | ZHA Qianqian, XU Lianying, CHEN Juan, HUANG Wen, ZHANG Xinqiong. Summary of Best Evidence for Prevention of Recurrence of Late-life Depression [J]. Chinese General Practice, 2023, 26(19): 2332-2338. |
[15] | CHEN Lulu, ZHANG Liping, LI Jingwen, DONG Wenjie, WU Xin'ai. Clinical Effect and Safety of PD-1 Inhibitors plus Fruquintinib as Later-line Treatment for Metastatic Colorectal Cancer [J]. Chinese General Practice, 2023, 26(18): 2262-2267. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||